These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38566053)

  • 41. Aqueous Humor-Derived MYD88 L265P Mutation Analysis in Vitreoretinal Lymphoma: A Potential Less Invasive Method for Diagnosis and Treatment Response Assessment.
    Demirci H; Rao RC; Elner VM; Demirci FY; Axenov L; Betz B; Behdad A; Brown N
    Ophthalmol Retina; 2023 Feb; 7(2):189-195. PubMed ID: 35952929
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88
    Deng T; Zhang S; Xiao M; Gu J; Huang L; Zhou X
    Cancer Med; 2024 Feb; 13(4):e7005. PubMed ID: 38457222
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
    Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
    Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MYD88
    Ferrante M; Furlan D; Zibellini S; Borriero M; Candido C; Sahnane N; Uccella S; Genuardi E; Alessandria B; Bianchi B; Mora B; Grimaldi D; Defrancesco I; Jiménez C; Cavallo F; Ferrero D; Dogliotti I; Merli M; Varettoni M; Ferrero S; Drandi D
    Diagnostics (Basel); 2021 Apr; 11(5):. PubMed ID: 33926007
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multiplex sequencing for EZH2, CD79B, and MYD88 mutations using archival cytospin preparations from B-cell non-Hodgkin lymphoma aspirates previously tested for MYC rearrangement and IGH/BCL2 translocation.
    Santos Gda C; Saieg MA; Ko HM; Geddie WR; Boerner SL; Craddock KJ; Crump M; Bailey D
    Cancer Cytopathol; 2015 Jul; 123(7):413-20. PubMed ID: 25807917
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence And Clinical Significance Of Oncogenic
    Chen YP; Ke LF; Lu JP; Wang JC; Zhu WF; Chen FF; Lin SF; Xu CW; Wu MJ; Chen G
    Onco Targets Ther; 2019; 12():10165-10175. PubMed ID: 32063711
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Circulating cell-free DNA and IL-10 from cerebrospinal fluids aid primary vitreoretinal lymphoma diagnosis.
    Zhuang Z; Zhang Y; Zhang X; Zhang M; Zou D; Zhang L; Jia C; Zhang W
    Front Oncol; 2022; 12():955080. PubMed ID: 36059608
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction.
    Janku F; Huang HJ; Fujii T; Shelton DN; Madwani K; Fu S; Tsimberidou AM; Piha-Paul SA; Wheler JJ; Zinner RG; Naing A; Hong DS; Karp DD; Cabrilo G; Kopetz ES; Subbiah V; Luthra R; Kee BK; Eng C; Morris VK; Karlin-Neumann GA; Meric-Bernstam F
    Ann Oncol; 2017 Mar; 28(3):642-650. PubMed ID: 27993791
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MYD88 p.(L265P) detection on cell-free DNA in liquid biopsies of patients with primary central nervous system lymphoma.
    Hiemcke-Jiwa LS; Leguit RJ; Snijders TJ; Bromberg JEC; Nierkens S; Jiwa NM; Minnema MC; Huibers MMH
    Br J Haematol; 2019 Jun; 185(5):974-977. PubMed ID: 30408153
    [No Abstract]   [Full Text] [Related]  

  • 50. Comparative Study on the Clinicopathologic and Molecular Characteristics of Primary and Secondary Diffuse Large B-cell Lymphoma in the Central Nervous System.
    DO J; Yenwongfai LN; DO SI; Kim SW; Na K
    Anticancer Res; 2024 Jul; 44(7):2953-2960. PubMed ID: 38925823
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma.
    Xie J; Shen X; Shi Q; Yi H; Ouyang B; Zhang Z; Gu Y; Dong L
    Hematol Oncol; 2022 Dec; 40(5):885-893. PubMed ID: 36053490
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.
    Lee JH; Jeong H; Choi JW; Oh H; Kim YS
    Sci Rep; 2017 May; 7(1):1785. PubMed ID: 28496180
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MYD88 L265P MUTATION DETECTION IN THE AQUEOUS HUMOR OF PATIENTS WITH VITREORETINAL LYMPHOMA.
    Miserocchi E; Ferreri AJM; Giuffrè C; Cangi MG; Francaviglia I; Calimeri T; Ponzoni M; Pecciarini L; Bandello FM; Modorati GM
    Retina; 2019 Apr; 39(4):679-684. PubMed ID: 30204732
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome.
    Rovira J; Karube K; Valera A; Colomer D; Enjuanes A; Colomo L; Martínez-Trillos A; Giné E; Dlouhy I; Magnano L; Delgado J; Martínez A; Villamor N; Campo E; López-Guillermo A
    Clin Cancer Res; 2016 Jun; 22(11):2755-64. PubMed ID: 26792260
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.
    Pham-Ledard A; Beylot-Barry M; Barbe C; Leduc M; Petrella T; Vergier B; Martinez F; Cappellen D; Merlio JP; Grange F
    JAMA Dermatol; 2014 Nov; 150(11):1173-9. PubMed ID: 25055137
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PlentiPlex™ MYD88 Waldenström lymphoma qPCR assay: A highly sensitive method for detection of MYD88 L265P mutation.
    Viscovo M; Clemmensen ML; Fosso F; Maiolo E; Autore F; Laurenti L; Hohaus S; Chiusolo P
    Int J Lab Hematol; 2024 Aug; 46(4):665-669. PubMed ID: 38390807
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of high-resolution melting analysis for the detection of the MYD88 L265P mutation.
    Wang CZ; Lin J; Qian J; Shao R; Xue D; Qian W; Xiao GF; Deng ZQ; Yang J; Li Y; Chen XX
    Clin Biochem; 2013 Mar; 46(4-5):385-7. PubMed ID: 23178471
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genomic Alterations and MYD88
    Jiang S; Qin Y; Gui L; Liu P; Jiang H; Liu B; Yang J; Yang S; He X; Zhou S; Du X; Yi Y; Lin J; Shi Y
    Target Oncol; 2020 Apr; 15(2):221-230. PubMed ID: 32239385
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas.
    Caner V; Sen Turk N; Baris IC; Cetin GO; Tepeli E; Hacioglu S; Sari I; Zencir S; Dogu MH; Bagci G; Keskin A
    Genet Test Mol Biomarkers; 2015 Jul; 19(7):372-8. PubMed ID: 25978699
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies.
    Bagratuni T; Ntanasis-Stathopoulos I; Gavriatopoulou M; Mavrianou-Koutsoukou N; Liacos C; Patseas D; Kanellias N; Migkou M; Ziogas DC; Eleutherakis-Papaiakovou E; Roussou M; Fotiou D; Terpos E; Kastritis E; Dimopoulos MA
    Leukemia; 2018 Dec; 32(12):2617-2625. PubMed ID: 30026568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.